A Mass Balance Study Following Subcutaneous Administration of [14C]-ITI-1284 to Healthy Male Subjects

Phase 1 Completed 8 enrolled Intra-Cellular Therapies, Inc.

NaSingle-groupOpen-labelTreatment

Summary

ITI-1284-012 is an open-label, single-dose study to assess the mass balance recovery of radioactivity, and to evaluate the pharmacokinetics, safety and tolerability of ITI-1284 after a single subcutaneous dose of \[14C\]-ITI-1284 in healthy male subjects.

Timeline

Start: 2025-01-28
Primary completion: 2025-03-26
Completion: 2025-03-26

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ITI-1284	Unknown	20 mg	Subcutaneous

Indications

No indication recorded.